1 Case report:

2 The impact of antibiotics on the presence of the protozoan anaerobe 3 Blastocystis and the surrounding microbiome: a case study

- 4
- Jamie M. Newton¹, William JS. Edwards¹, Gary Thompson², Eleni Gentekaki^{4,5}, Anastasios
 D. Tsaousis^{1*}
- 7

8	¹ Laboratory of Molecular and Evolutionary Parasitology, RAPID group, School of
9	Biosciences, University of Kent, Canterbury, UK;
10	² NMR Facility, School of Biosciences, University of Kent, Canterbury, CT2 7NJ, UK
11	³ East Kent Hospitals University NHS Trust, Ashford
12	⁴ School of Biosciences, University of Kent, Canterbury, CT2 7NJ, UK
13	⁵ University of Nicosia School of Veterinary Medicine, 2414, Nicosia, Cyprus;
14	
15	*Corresponding author: Dr. Anastasios D. Tsaousis: a.tsaousis@kent.ac.uk
16	
17	
17	
18	
19	

21

20

22

23 Abstract

Background: *Blastocystis*, the most prevalent eukaryotic gut microbe in humans, has a global distribution. Studies have linked its presence with distinct gut microbiome and metabolome profiles compared to those where the organism is absent. However, the in vivo effect of antibiotics on *Blastocystis* and the surrounding gut microbiome remains understudied. This case study aimed to explore how antibiotic consumption influences the presence of *Blastocystis* and the subsequent changes in the gut microbiome and metabolome of an individual with irritable bowel syndrome (IBS).

Methods: Stool samples from an IBS patient, collected at various time points, were tested for *Blastocystis* presence using RT-PCR targeting the *SSUrRNA* gene, followed by sequencing of positive samples. Illumina sequencing determined the gut microbiome composition, while one-dimensional proton NMR spectroscopy analysed the metabolome composition. Statistical analyses were conducted to identify relationships between antibiotic consumption, bacterial diversity, metabolome composition, and *Blastocystis* presence.

37 Results: Antibiotics significantly impacted the gut microbiome, with diversity declining early 38 in the antibiotic course, then recovering later and post-course. *Blastocystis* was detected early, 39 late, and post-course but not mid-course, coinciding with the decline in bacterial diversity. No 40 significant differences were observed between *Blastocystis*-positive and *Blastocystis*-negative samples. However, bacterial composition significantly differed between samples collected 41 42 before, early, and after the antibiotic course compared to those collected mid-course. 43 Metabolite groups, including short-chain fatty acids, amino acids, and succinate, exhibited changes throughout the antibiotic course, indicating that gut metabolite composition is 44 45 affected by antibiotic consumption.

46

47	Discussion/Conclusion: While antibiotics did not significantly impact Blastocystis
48	colonisation, they did cause a mid-course decline in microbial diversity and Blastocystis
49	presence. The study also revealed significant alterations in important metabolites such as
50	SCFAs and amino acids throughout the antibiotic course, with an altered metabolome
51	observed post-course. This case study underscores the complex interactions between
52	antibiotics, gut microbiota, and metabolites, highlighting the resilience of Blastocystis in the
53	gut ecosystem.
54	
55	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
65	

66

67 Introduction

The gut microbiome and metabolome are crucial influencers of gastrointestinal (GI) health, 68 69 and their interactions can be better understood by studying them in tandem [1]. This dual 70 approach is particularly important when investigating GI health differences across various 71 cohorts or when external factors influence the GI tract. For example, a previous 72 metabolomics study using ^1H Nuclear Magnetic Resonance (NMR) spectroscopy revealed 73 significant differences in stool metabolite composition between individuals with diarrhoea 74 and healthy controls and between *Blastocystis* carriers and non-carriers [2]. Understanding 75 these interactions can provide deeper insights into the complex dynamics of gut health and 76 disease.

77 Blastocystis is a eukaryotic microbe that resides in the GI tract and has a global distribution in 78 a broad range of animal hosts [3], [4]. Epidemiological studies and phylogenetic analysis of 79 the small subunit ribosomal RNA (SSU rRNA) gene have revealed over 44 different subtypes, 80 twelve of which STs 1-9, 12, 16, 23 have been identified in human stool samples [5], [6], [7], 81 [8], [9]. Blastocystis was initially designated as a parasite and linked with IBS and other 82 gastrointestinal disorders [10], [11]; however, more recent studies have indicated a negative 83 correlation between the presence of the organism and gastrointestinal symptoms [8], [9], [12], 84 [13], () muddling its association with disease. *Blastocystis*' genetic diversity further 85 complicates interpretations, with many studies finding no relationship between inter and intra-subtype diversity and disease [9], [12]. 86

Nonetheless, specific microbial profiles have been associated with the organism. For
instance, *Blastocystis* presence is more common in the *Ruminococcaceae* and *Prevotella*enterotypes, rather than *Bacteroides*, and associated with higher richness and diversity, which

can be an indicator of good GI health [8], [14], [15]. At the level of subtype, *Blastocystis* ST3
and ST4 have been shown to have an inverse relationship with *Akkermansia* abundance, an
indicator of GI health [8]. Whether *Blastocystis* is a gut ecosystem engineer, a simple
colonizer or just a passenger is still unknown.

94 Individuals with irritable bowel syndrome (IBS) have been known to have distinct gut 95 bacterial compositions/profiles to their non-IBS counterparts, making IBS treatment with 96 antibiotics a potential influencing factor [16], [17], [18], [19]. In vivo and in vitro studies 97 have indicated that the gut microbiomes of individuals colonised with Blastocystis show a 98 decline in abundance of genera such as *Bifidobacterium* and *Lactobacillus* [15], [20], [21]. 99 Bifidobacterium has a role in immunomodulation and protection of the GI epithelial cells 100 [20], [22], [23]. Therefore, the results of these studies could link *Blastocystis* to dysbiosis-101 induced GI symptoms and possibly IBS.

Antibiotic administration has been an effective treatment for some IBS cases and other GI conditions, while metronidazole, ciprofloxacin and rifaximin have been effective at decreasing the severity of symptoms in many clinical trials [18], [19], [24], [25], [26]. However, as our understanding of the gut microbiome's role in gastrointestinal health deepens, the impact of antibiotics on gut microbiota modulation is receiving closer scrutiny. Several studies have detected significant changes in the gut microbiome composition during antibiotic treatment and, occasionally, microbiome recovery after treatment [27], [28], [29].

In this case study, we monitored the metabolome and the bacterial gut microbiome composition of a *Blastocystis*-positive IBS patient during a 14-day course of antibiotics. We also analysed *Blastocystis* presence over this 14-day period and how it is impacted by antibiotic treatment. The subject's gut microbiome and metabolome composition were also

analysed following the termination of the antibiotic course to monitor microbial diversity

114 recovery after *Blastocystis* detection.

115

116 Materials and Method

117 Ethics approval

The study was conducted within the guidelines established in IRAS ethics approvals 274985
and 286641, following a review by an ethics committee and applying suggested amendments
to comply with ethical standards. The UK National Ethic committees of Health Research
Authority (HRA) and Health and Care Research Wales (HCRW) under the umbrella of NHS
Health Research Authority gave ethical approval of this work.

123

124 Participant recruitment and sample collection

125 The study subject, previously diagnosed with IBS, presented to a hospital in the Kent county 126 (South East England) with gastrointestinal symptoms and was put on a 14-day course of antibiotics. These included 500 mg Amoxicillin (a 3rd generation penicillin antibiotic) x 2 and 127 500 mg Clarithromycin (a 2nd generation macrolide antibiotic). Daily doses of 30 mg 128 129 Lansoprazole (proton pump inhibitor) x 2 was also prescribed. The subject was in their 40s 130 (41 to 45) with a BMI of 29 and a mixed diet. The subject was provided with faeces catchers 131 (Zymo Research Cat No R1101-1-10) and two types of collection tubes, one containing 5 ml 132 DNA/RNA shield (Zymo Research Cat No R1100-250) and the other containing 5 ml of 50% 133 methanol. Each faecal sample was distributed in the two tubes. Faecal samples were collected 134 just before the commencement of the treatment course, then on D2 then once daily for the 135 remainder of the first week, then once on D8, D10 and D15 (the day after the completion of

the course) for the following week. Follow-up samples were then collected at D30 and D3M
(3 months after course start). The samples were stored in their respective tubes in DNA/RNA
shield or methanol at -80°C.

139

140 DNA extraction

200 mg solid stool stored in DNA/RNA shield or 200 µl liquid stool were added to 200 µl
PBS (pH 7.4 RNAase free). The samples were then centrifuged for 10 minutes at 10,000 x g
at room temperature (RT). The pellet was then resuspended in the supernatant and the DNA
was extracted using the QIAamp PowerFecal Pro DNA Kit (Qiagen; Cat. No: 51804)
following the manufacturer's protocol, and 50 µl DNA was eluted.

146

147 <u>qPCR and Blastocystis detection</u>

148 For *Blastocystis* detection, a 350 bp region of the SSU rRNA gene was targeted using a 149 reaction mixture of 2 µl DNA, 500 nM of primer set PPF1 (fwd) (5'-150 AGTAGTCATACGCTCGTCTCAAA-3') and R2PP (rvs) (5'-TCTTCGTTACCCGTTACTGC-3') and 5 µl SYBR green making a full reaction volume of 151 152 10 µl. The qPCR was run on a Quantstudio-3 real-time PCR machine with the following 153 program: initial denaturation 95 °C for 5 minutes, then 45 cycles of initial denaturation 95°C 154 for 5 seconds, annealing 68 °C for 10 seconds, extension 72°C 10 seconds then a final 155 extension of 72 °C for15 seconds.

156

157 <u>Sequencing and Subtype annotation</u>

158 Bi-directional Sanger sequencing using the set of primers for the qPCR reaction was 159 outsourced to and performed by Eurofins (UK). The forward and reverse nucleotide 160 sequences were then assessed and trimmed using SnapGene Viewer Version 6.2.2 161 (https://www.snapgene.com/snapgene-viewer). The final trimmed consensus sequences were 162 then used as queries to check for contamination using the Basic Local Alignment Search Tool Biotechnology 163 (BLAST) National from the Centre for Information (NCBI) (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Once the identity of the sequence was confirmed as 164 165 *Blastocystis*, the subtype was assigned using the curated database pubMLST (https://pubmlst.org/organisms/blastocystis-spp). 166

167

168 <u>16S rRNA gene amplicon sequencing</u>

169 Novogene outsourced the high-throughput amplicon sequencing. The protocol used was 170 based on Caporaso et al [30]. [] with some modifications. One ng DNA from extracts was 171 used, fragmented, and then adapted for paired-end sequencing. The DNA was amplified 172 using the primer pair 515F GTGCCAGCMGCCGCGGTAA and 907R 173 CCGTCAATTCCTTTGAGTTT, which amplifies the hypervariable region and then 174 sequenced on the Illumina NovaSeq platform.

The raw reads were classified using the Lotus2 software [[31]]. The parameters and tools used are as follows: Chimera checking/removal was performed using Minimap2 [[32]], and Minimap2 was also used to look for off-target hits containing human DNA 'contaminated' reads by BLASTing reads against Genome Reference Consortium Human Build 38.p14. V3-V4 region trimmed reads were then clustered into ASVs (\leq 1 nucleotide dissimilarity) using Divisive Amplicon Denoising Algorithm 2 (DADA2) [[33]], ASVs were taxonomically classified (to species level) using BLAST against the GreenGenes2 (GG2) database [[34]].

182 GG2 was chosen for its reliability (GG2 is a unified database suitable for whole genome
183 sequencing (WGS) data and 16s data), as well as replicable results.

184

185 <u>Statistical analysis</u>

186 Statistical analysis and data visualisation were done using the R Studio 4.2.3 package. 187 Relative abundances of each genus were calculated in each sample, and a heatmap was 188 constructed. Diversity index values were calculated using the Phyloseq package. Shannon, 189 Chao1, Simpson and observed taxa values were used. These four values were analysed for 190 statistical differences occurring between the *Blastocystis* positive and *Blastocystis* negative 191 samples, as well as differences in diversity score between the 'antibiotic positive' time points 192 (days 4-15) and the 'antibiotic negative' time points (day 0, 30 days post antibiotics and 3 193 months post antibiotics). First, a Shapiro test was used to determine the data distribution to 194 analyse the statistical differences between the sample groups. Normally distributed data was 195 analysed with ANOVA test followed by Tukey HSD test for pairwise comparison. For 196 samples with a non-normal distribution, the Kruskal-Wallis test was used, followed up by the 197 Dunn Test (Bonferroni P-adjust) for pairwise comparisons. The raw diversity index values 198 were also plotted over time. To visualise microbiome composition, compositional plots 199 showing all taxa making up >1% of the total read counts were produced using the 200 Microbiome package. To look for the presence of 'bio-markers' of the presence of 201 Blastocystis, Linear Discriminant Effect Size (LEfSe) analysis was done [35]. LEfSe uses a 202 combination of statistical tests to identify taxa whose high/low abundance or 203 presence/absence allows for the best linear discrimination/explanation of the differences 204 observed (changes in taxa) between the 2 groups of samples (*Blastocystis* +ve/-ve). Principle 205 Component Analysis (PCA) was also used to determine differences between the *Blastocystis*

+ve/-ve groups based on overall taxa presence and distribution. Samples were plotted based
on their Dissimilarity matrix values (Euclidian distances), and principal component analysis
was performed. Statistical analysis was then done using PERMANOVA [[34]] to determine if
the 'centrons' of each group (*Blastocystis* +ve/-ve) differed significantly in location.

210

211 <u>Metabolite extraction</u>

212 200 mg solid stool stored in methanol or 200 μ l liquid stool was resuspended in 4 ml 213 methanol, then 200 mg glass beads were added and vortexed for 30 seconds. The samples 214 were then incubated at RT for 3 minutes, then vortexed for a further 30 seconds. The 215 supernatants were then divided in 4 x 1m aliquots then centrifuged at 10,000 x g at 4°C for 20 216 mins then lyophilized. The lyophilized desiccates were then resolubilised in 375 μ l 10% D₂O 217 1 mM non-deuterated DSS and recombined to make 1.5 ml solutions for NMR analysis.

The extracts were run on a 600 MHz Avance III NMR spectrometer (Bruker) with QCI-P cryoprobe at a calibrated temperature of 298K to acquire $1D^{-1}H$ spectra. For each sample an automated program was set up on the spectrometer using ICON NMR including measurement of water offset, 90° pulse calibration, locking to D₂O, tuning and shimming using an excitation sculpting experiment. A $1D^{-1}H$ -NOESY was run with a mixing time of 100 ms, 512 scans and 8 dummy scans, a spectral width of 15.98 ppm (9.59 Hz), 32768 data points, an acquisition time of 2.27 s and a relaxation delay of 3 s.

The NMR spectra were phased, baseline corrected and had a 1 Hz exponential line broadening window function applied using TOPSPIN 3.6.1 (Bruker) software, then exported into Chenomx 8.4. The water resonance peak between 4.56 pmm and 4.97 ppm was deleted. The spectral peaks were then fit into the Chenomx library of metabolites using the profiler tool to match the peaks to their corresponding metabolites and concentrations.

230	Metabolites at significantly high abundances and of biological importance were divided into
231	four groups; Short chain fatty acids (SCFAs), amino acids, sugars and sugar alcohols and
232	other important metabolites and a time course was plotted to show the change in abundance
233	of each metabolite throughout the antibiotic course.

234

235 Results and Discussion

236 <u>Composition of gut bacterial communities and *Blastocystis* colonisation</u>

Stool samples from days 0, 2, 3, 4, 5, 6, 7, 8, 10, 15, 30 days and 3 months after the start of
the antibiotic course were collected and processed for both *Blastocystis* screening and 16S
gut microbiome analysis. *Blastocystis* ST1 was present in samples from D2, D3 and
consistently after D8 (**Table 1**).

241 For the microbiome analysis, the most abundant genera (defined here as taxa whose mean 242 abundance across all samples exceeded 1% of the total read count) across all stool samples 243 were plotted as a heatmap and compositional plot (Figures 1 - 2). Seventeen genera met 244 these criteria, while multiple genera showed patterns of change throughout the antibiotic 245 course, including *Phocaeicola_A*, *Escherichia* and *Enterococcus_B* (Figures 1 - 2). Samples 246 were also grouped by their similarity values (Euclidean distance scores) and ordered in a 247 dendrogram. The bacterial communities of the samples collected 30 days and three months 248 after the start of the antibiotic course were more similar in taxonomic distribution to the 249 samples taken at both ends of the antibiotic course (D0-2 and D10-15) and had the least 250 similarity to samples taken on D3-D7 (Figure 1). The samples collected on D0 and D2 were 251 strongly similar to each other. Bacteroides and Phocaeicola (both from the phylum 252 Bacteroidota) were the most abundant genera. They became more dominant throughout the 253 first week of the course, with their relative abundances decreasing in the months after the

254 completion of the course (Figures 1 - 2). *Phocaeicola* was the dominant genus and showed 255 an increase in relative abundance in the first four days of the course, a slight decrease towards 256 the end of the course and a further decrease in the months following the course (Figure 2). 257 *Phocaeicola* was no longer the dominant genus after the antibiotic course, with *Escherichia* 258 and *Enterococcus* being the most abundant in D30 and D3M, respectively (Figure 2). 259 Blastocystis was not detected on D3, D4, D5, D6 and D7 of the course, but was again 260 detected on D8 and recovered at the end. The presence of Blastocystis coincided with the 261 decrease in abundance of *Bacteroides* and *Phocaeicola* (Figure 2). The reduced abundance 262 of *Bacteroides* in the presence of *Blastocystis* is a consistent finding across studies globally 263 [8], [14], [36], [37], [38], [39].

264

265 Impact of antibiotic course on alpha diversity

266 To measure changes on alpha diversity, Shannon (factors in both evenness and richness), 267 Chao1 (richness index which factors in potentially relevant singleton and doubleton 'rare 268 taxa'), Simpson (a measure of 'dominance'/degree to which a few taxa make up most of the 269 reads) and Observed taxa (true richness) indices were used. These diversity indices were 270 analysed at the antibiotic-negative stage (pooled data of timepoints D0, D30, D3M) and at the 271 antibiotic-positive stage (pooled data of timepoints D2, D3, D4, D5, D6, D7, D8, D10 and 272 D15). All four metrics decreased during antibiotic administration. Antibiotics have been 273 associated with acute gut microbiota perturbations defined by a decrease in taxonomic 274 diversity [40], [41] (). However, these changes when analysed by ANOVA/Kruskal-Wallis 275 were shown to be non-significant (>0.05 P-value) (Supplementary Figure 1 B,D,F,H).

The diversity metric scores were also plotted individually over time. The Shannon andSimpson diversity metrics decreased during the antibiotic course however the baseline

278	composition recovered in the months after the course ended, although a decreasing trend was
279	observed in D3M (Figure 3 A, D). This observation aligns with previous studies in both
280	adults and children whereby core microbiome taxa return to their pre-antibiotics abundance
281	[42]. Chao1 and Observed taxa showed sharp reductions at D4, D6 and D15. The reduction
282	in these two indices on D15 contrasts the increase in the Shannon diversity score, indicating
283	that the recovery in Shannon diversity score towards the end/post antibiotics course was
284	characterised by a matching reduction in domination of the microbiome by a handful of taxa.
285	This could be attributed to the elimination of rare taxa by the antibiotics.

286

287 <u>Alpha diversity of Gut Microbial communities and *Blastocystis* colonisation</u>

Blastocystis was detected early and later in the antibiotic course but not between D4 and D7 (Figure 3). All examined metrics of alpha diversity of *Blastocystis*-positive stool were increased when compared to the *Blastocystis*-negative stool (Figure 3; Supplementary Figure 1). These changes in diversity were analysed for statistical significance and found to all be non-significant (Observed taxa and Chao1 showed very low P-values of 0.058 and 0.064, respectively).

294

295 Biomarker analysis of stool samples for *Blastocystis* colonisation

Having shown that (non-significant) increases in diversity occur with the presence of *Blastocystis* in stool samples, LEfSe was used to look for biomarkers of this change. LEfSE [35] locates taxa whose presence/absence allows for the best identification of a member of the Blastopos group instead of a member of the Blastoneg group [35]. Any LDA score >2 or <-2 is considered to be significant (**Figure 4**) shows all taxa with a significant LDA score and are coloured to show the indicative group. As shown in the plot, only two taxa were

302 significantly viable at discriminating against the two groups in favour of *Blastocystis* negative 303 samples (red, Blastoneg); these taxa were an unclassified member of the family 304 Anaerotignaceae and the genus Lactobacillus. There was a considerably larger amount of 305 taxa that were indicative of the *Blastocystis* positive group, with five taxa with a <-4 LDA 306 score (Supplementary Figure 2); an unclassified member of the *Negativicutes* class of 307 bacteria, an unclassified *Firmicute* bacteria, two different unclassified members of the family 308 Rikenellaceae and an unclassified member of the family Enterobacteriaceae. The data 309 suggests that some bacteria are indicators of the presence of *Blastocystis*. Still, the presence 310 of so many indicative taxa may imply that a more diverse microbiome is the true indicative 311 factor for Blastocystis.

312

313 <u>Impact of antibiotic course on metabolite composition of the gut and *Blastocystis* 314 <u>colonisation</u> </u>

315 The metabolite extracts from the stool samples were subjected to 1D¹H NMR. Based on their 316 chemical properties, four groups of metabolites were detected, including short-chain fatty 317 acids (SCFAs) (Figure 5a), amino acids (Figure 5b), sugars and sugar alcohols (Figure 5c) 318 and others (Figure 5d). Previous metabolome investigations at a single timepoint on 319 Blastocystis positive and negative individuals showed a decreased abundance of certain 320 metabolites in the former [2]. Specifically, Alanine, Glycine, Histidine, Isoleucine, 321 Methionine, Threonine, Tryptophan and Valine all decreased, suggesting an anti-322 inflammatory role of *Blastocystis*. Significant increases in certain amino acids in the stool 323 have been found in IBD patients [43]. Herein, in a time course metabolome of a single 324 individual, all the amino acids, particularly Alanine and Valine, showed a decrease mid-325 course and recovery towards the end of the course.

326 Moreover, all amino acids, but glutamate showed a large decrease post-course (Figure 5b). 327 Regarding SCFAs, the abundance of acetate increased throughout the first week of the 328 antibiotic course but decreased during the second week and then recovered post-course. 329 Butyrate increased after the first four days, decreased on D7, and recovered post-course. 330 Whether these alterations reflect changes in absorption or loss remains an open question. 331 Cellobiose was the most impacted sugar by the antibiotic course and showed a large increase 332 in abundance during the first week, then decline and recovery during the second week 333 (Figure 5c). Malonate steadily declined for the first five days and was undetectable by D6. It 334 then recovered on D7, D8 and D10 but became undetectable on D15 and post-course (Figure 335 5d). Succinate sharply increased from D1 to D2 and stayed high until D5, when it declined 336 again. O-acetylcholine declined for the first five days then recovered on D6 and D7, but 337 disappeared during the second week and didn't recover post-course. Notably, acetylcholine in 338 the gut plays a role in intestinal homeostasis; hence, its disruption could potentially aggravate 339 inflammation [44].

340

341 Conclusion

This case study provides valuable insights into the impact of antibiotic treatment on the presence of *Blastocystis* and the overall gut microbiome and metabolome. The 14-day course of Lansoprazole, Amoxicillin, and Clarithromycin significantly altered the gut microbial composition, causing a notable decline in microbial diversity mid-course and leading to a temporary absence of *Blastocystis*. Despite the antibiotic-induced perturbations, *Blastocystis* demonstrated resilience, re-emerging post-treatment.

Additionally, the study highlighted significant fluctuations in metabolite levels, including short-chain fatty acids and amino acids, which are critical for gut health. These changes

underscore the profound influence antibiotics have not only on microbial populations but also on the metabolic environment of the gut. While antibiotics did not have a lasting effect on *Blastocystis* colonisation, their temporary impact on microbial diversity and metabolite composition points to gut ecology's intricate and dynamic nature. The findings emphasise the need for careful consideration of antibiotic use, especially in conditions like IBS, where maintaining a balanced gut microbiome is crucial.

Future research should expand on these findings by exploring the long-term effects of antibiotics on gut microbiota and metabolites in larger cohorts. Understanding these interactions will be essential for developing targeted therapies that mitigate adverse impacts on the gut ecosystem while effectively treating gastrointestinal conditions.

360

361 Acknowledgements

We would like to thank the volunteer for participating in this study. Many thanks to the Tsaousis Lab members (2020 – 2021) for their help and support in sample collection and managing this project. J.M.N. was supported by a Kent Health studentship and W.J.S.E. by a SoCoBio DTP studentship.

366

367 Contributions

Conceptualisation, A.D.T.; methodology, J.M.N., W.J.S.E. and G.S.T.; software, G.S.T.; validation, G.S.T. and W.G. and W.J.S.E..; formal analysis, J.M.N. and W.J.S.E.; investigation, J.M.N. and W.J.S.E.; resources, A.D.T.; data curation, J.M.N. and E.G.; writing—original draft preparation, J.M.N.; writing—review and editing, A.D.T., E.G.;

372	supervision, A.D.T.; project administration, A.D.T.; funding acquisition, A.D.T. All authors					
373	have read and agreed to the published version of the manuscript.					
374						
375						
376						
377						
378	Ref	erences				
379						
380 381	[1]	A. Visconti <i>et al.</i> , "Interplay between the human gut microbiome and host metabolism," <i>Nat Commun</i> , vol. 10, no. 1, Dec. 2019, doi: 10.1038/s41467-019-12476-z.				
382 383 384	[2]	E. L. Betts <i>et al.</i> , "Metabolic fluctuations in the human stool obtained from blastocystis carriers and non-carriers," <i>Metabolites</i> , vol. 11, no. 12, Dec. 2021, doi: 10.3390/metabo11120883.				
385 386 387	[3]	K. S. W. Tan, "Blastocystis in humans and animals: New insights using modern methodologies," <i>Vet Parasitol</i> , vol. 126, no. 1-2 SPEC.ISS., pp. 121–144, 2004, doi: 10.1016/j.vetpar.2004.09.017.				
388 389 390	[4]	K. S. W. Tan, "New insights on classification, identification, and clinical relevance of Blastocystis spp.," <i>Clin Microbiol Rev</i> , vol. 21, no. 4, pp. 639–665, 2008, doi: 10.1128/CMR.00022-08.				
391 392	[5]	B. Skotarczak, "Genetic diversity and pathogenicity of blastocystis," <i>Annals of Agricultural and Environmental Medicine</i> , vol. 25, no. 3, pp. 411–416, 2018, doi: 10.26444/aaem/81315.				
393 394 395	[6]	S. K. Kamaruddin, A. Mat Yusof, and M. Mohammad, "Prevalence and subtype distribution of Blastocystis sp. in cattle from Pahang, Malaysia," <i>Trop Biomed</i> , vol. 37, no. 1, pp. 127–141, 2020.				
396 397 398	[7]	J. G. Maloney <i>et al.</i> , "Identification and Molecular Characterization of Four New Blastocystis Subtypes Designated ST35-ST38," <i>Microorganisms</i> , vol. 11, no. 1, Jan. 2023, doi: 10.3390/microorganisms11010046.				
399 400 401	[8]	R. Y. Tito <i>et al.</i> , "Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota," <i>Gut</i> , vol. 68, no. 7, pp. 1180–1189, Jul. 2019, doi: 10.1136/gutjnl-2018-316106.				
402 403	[9]	M. J. Kim, E. J. Won, S. H. Kim, J. H. Shin, and J. Y. Chai, "Molecular detection and subtyping of human blastocystis and the clinical implications: Comparisons between diarrheal				

404 405		and non-diarrheal groups in korean populations," <i>Korean Journal of Parasitology</i> , vol. 58, no. 3, pp. 321–326, 2020, doi: 10.3347/kjp.2020.58.3.321.
406 407 408	[10]	C. R. Stensvold <i>et al.</i> , "Blastocystis: Unravelling potential risk factors and clinical significance of a common but neglected parasite," <i>Epidemiol Infect</i> , vol. 137, no. 11, pp. 1655–1663, 2009, doi: 10.1017/S0950268809002672.
409 410	[11]	A. M. Abdulsalam <i>et al.</i> , "Prevalence, predictors and clinical significance of Blastocystis sp. in Sebha, Libya," <i>Parasit Vectors</i> , vol. 6, no. 86, pp. 1–8, 2013, doi: 10.1186/1756-3305-6-86.
411 412 413 414	[12]	A. Alinaghizade, H. Mirjalali, M. Mohebali, C. R. Stensvold, and M. Rezaeian, "Inter- and intra-subtype variation of Blastocystis subtypes isolated from diarrheic and non-diarrheic patients in Iran," <i>Infection, Genetics and Evolution</i> , vol. 50, pp. 77–82, 2017, doi: 10.1016/j.meegid.2017.02.016.
415 416 417	[13]	E. Piperni <i>et al.</i> , "Intestinal Blastocystis is linked to healthier diets and more favorable cardiometabolic outcomes in 56,989 individuals from 32 countries," <i>Cell</i> , 2024, doi: 10.1016/j.cell.2024.06.018.
418 419 420	[14]	J. Forsell, J. Bengtsson-Palme, M. Angelin, A. Johansson, B. Evengård, and M. Granlund, "The relation between Blastocystis and the intestinal microbiota in Swedish travellers," <i>BMC Microbiol</i> , vol. 17, no. 231, pp. 1–9, 2017, doi: 10.1186/s12866-017-1139-7.
421 422 423	[15]	A. Kodio <i>et al.</i> , "Blastocystis colonization is associated with increased diversity and altered gut bacterial communities in healthy malian children," <i>Microorganisms</i> , vol. 7, no. 649, pp. 1–12, 2019, doi: 10.3390/microorganisms7120649.
424 425	[16]	K.L Glassner, B.P Abraham, E.M.M. Quigley "The microbiome and inflammatory bowel disease," <i>J Allergy Clin Immunol</i> , vol. 145, no. 1, pp. 16–27, Jan. 2020.
426 427 428	[17]	C. Milani <i>et al.</i> , "The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiology <i>and Molecular Biology Reviews</i> , vol. 81, no. 4, 2017, doi: 10.1128/mmbr.00036-17.
429 430 431	[18]	P. Rutgeerts <i>et al.</i> , "Controlled trial of metronidazole treatment for prevention of crohn's recurrence after ileal resection," <i>Gastroenterology</i> , vol. 108, no. 6, pp. 1617–1621, 1995, doi: 10.1016/0016-5085(95)90121-3.
432 433 434	[19]	L. R. Glick <i>et al.</i> , "Low-Dose Metronidazole is Associated with a Decreased Rate of Endoscopic Recurrence of Crohn's Disease after Ileal Resection: A Retrospective Cohort Study," <i>J Crohns Colitis</i> , vol. 13, no. 9, pp. 1158–1162, 2019, doi: 10.1093/ecco-jcc/jjz047.
435 436 437	[20]	J. A. Yason, Y. R. Liang, C. W. Png, Y. Zhang, and K. S. W. Tan, "Interactions between a pathogenic Blastocystis subtype and gut microbiota: In vitro and in vivo studies," <i>Microbiome</i> , vol. 7, no. 30, pp. 1–13, 2019, doi: 10.1186/s40168-019-0644-3.
438 439 440	[21]	C. Audebert <i>et al.</i> , "Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota," <i>Sci Rep</i> , vol. 6, no. April, pp. 1–11, 2016, doi: 10.1038/srep25255.
441 442 443	[22]	H. Li <i>et al.</i> , " <i>Bifidobacterium</i> spp. and their metabolite lactate protect against acute pancreatitis via inhibition of pancreatic and systemic inflammatory responses," <i>Gut Microbes</i> , vol. 14, no. 1, Dec. 2022, doi: 10.1080/19490976.2022.2127456.

A. Sivan *et al.*, "Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti–PD-L1 efficacy," *Science (1979)*, vol. 350, no. 6264, pp. 1084–1089, Nov. 2015, doi: 10.1126/science.aac4255.

- K.T. Thia *et al.*, "Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study," *Inflamm Bowel Dis*, vol. 15, no. 1, pp. 17–24, 2009, doi: 10.1002/ibd.20608.
- B. Shen *et al.*, "A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis," *Inflamm Bowel Dis*, vol. 7, no. 4, pp. 301–305, 2001, doi: 10.1097/00054725-200111000-00004.
- [26] B. E. Lacy, L. Chang, S. S. C. Rao, Z. Heimanson, and G. S. Sayuk, "Rifaximin Treatment for
 Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis
 Using New End Points," *Clin Ther*, vol. 45, no. 3, pp. 198–209, Mar. 2023, doi:
 10.1016/j.clinthera.2023.01.010.
- M. Willmann *et al.*, "Distinct impact of antibiotics on the gut microbiome and resistome: A
 longitudinal multicenter cohort study," *BMC Biol*, vol. 17, no. 1, Sep. 2019, doi:
 10.1186/s12915-019-0692-y.
- 460 [28] M. Reyman *et al.*, "Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial," *Nat Commun*, vol. 13, no. 1, Dec. 2022, doi: 10.1038/s41467-022-28525-z.
- 463 [29] T. Nogueira, P. H. C. David, and J. Pothier, "Antibiotics as both friends and foes of the human gut microbiome: The microbial community approach," Feb. 01, 2019, *Wiley-Liss Inc.* doi: 10.1002/ddr.21466.
- J. G. Caporaso *et al.*, "Global patterns of 16S rRNA diversity at a depth of millions of
 sequences per sample," *Proc Natl Acad Sci U S A*, vol. 108, no. SUPPL. 1, pp. 4516–4522,
 Mar. 2011, doi: 10.1073/pnas.1000080107.
- E. Özkurt *et al.*, "LotuS2: an ultrafast and highly accurate tool for amplicon sequencing analysis," *Microbiome*, vol. 10, no. 1, Dec. 2022, doi: 10.1186/s40168-022-01365-1.
- 471 [32] H. Li, "Minimap2: Pairwise alignment for nucleotide sequences," *Bioinformatics*, vol. 34, no.
 472 18, pp. 3094–3100, Sep. 2018, doi: 10.1093/bioinformatics/bty191.
- [33] B. J. Callahan, P. J. McMurdie, M. J. Rosen, A. W. Han, A. J. A. Johnson, and S. P. Holmes,
 "DADA2: High-resolution sample inference from Illumina amplicon data," *Nat Methods*, vol.
 13, no. 7, pp. 581–583, Jul. 2016, doi: 10.1038/nmeth.3869.
- 476 [34] T. Z. DeSantis *et al.*, "Greengenes, a chimera-checked 16S rRNA gene database and
 477 workbench compatible with ARB," *Appl Environ Microbiol*, vol. 72, no. 7, pp. 5069–5072, Jul.
 478 2006, doi: 10.1128/AEM.03006-05.
- [35] N. Segata *et al.*, "Metagenomic biomarker discovery and explanation," *Genome Biol*, vol. 12, no. 6, Jun. 2011, doi: 10.1186/gb-2011-12-6-r60.
- [36] F. Beghini, E. Pasolli, T. D. Truong, L. Putignani, S. M. Cacciò, and N. Segata, "Large-scale comparative metagenomics of Blastocystis, a common member of the human gut microbiome," *ISME Journal*, vol. 11, no. 12, pp. 2848–2863, Dec. 2017, doi: 10.1038/ismej.2017.139.

- [37] S. Gabrielli, F. Furzi, L. Fontanelli Sulekova, G. Taliani, and S. Mattiucci, "Occurrence of Blastocystis-subtypes in patients from Italy revealed association of ST3 with a healthy gut microbiota," *Parasite Epidemiol Control*, vol. 9, May 2020, doi: 10.1016/j.parepi.2020.e00134.
- [38] L. O'Brien Andersen *et al.*, "Associations between common intestinal parasites and bacteria in humans as revealed by qPCR," *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 35, no. 9, pp. 1427–1431, Sep. 2016, doi: 10.1007/s10096-016-2680-2.
- 492 [39] A. Rajamanikam, M. N. M. Isa, C. Samudi, S. Devaraj, and S. K. Govind, "Gut bacteria
 493 influence Blastocystis sp. phenotypes and may trigger pathogenicity," *PLoS Negl Trop Dis*,
 494 vol. 17, no. 3, 2023, doi: 10.1371/journal.pntd.0011170.
- 495 [40] L. McDonnell *et al.*, "Association between antibiotics and gut microbiome dysbiosis in
 496 children: systematic review and meta-analysis," *Gut Microbes*, vol. 13, no. 1, pp. 1–18, 2021,
 497 doi: 10.1080/19490976.2020.1870402.
- 498 [41] W. E. Anthony *et al.*, "Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults," *Cell Rep*, vol. 39, no. 2, Apr. 2022, doi: 10.1016/j.celrep.2022.110649.
- A. Palleja *et al.*, "Recovery of gut microbiota of healthy adults following antibiotic exposure," *Nat Microbiol*, vol. 3, no. 11, pp. 1255–1265, Oct. 2018, doi: 10.1038/s41564-018-0257-9.
- 503 [43] S. Bosch *et al.*, "Fecal Amino Acid Analysis Can Discriminate *De Novo* Treatment □ Naïve
 504 Pediatric Inflammatory Bowel Disease From Controls," *J Pediatr Gastroenterol Nutr*, vol. 66,
 505 no. 5, pp. 773–778, May 2018, doi: 10.1097/MPG.00000000001812.
- J. Uwada, H. Nakazawa, I. Muramatsu, T. Masuoka, and T. Yazawa, "Role of Muscarinic
 Acetylcholine Receptors in Intestinal Epithelial Homeostasis: Insights for the Treatment of
 Inflammatory Bowel Disease," Apr. 01, 2023, *Multidisciplinary Digital Publishing Institute*(MDPI). doi: 10.3390/ijms24076508.

510

Table 1 Blastocystis colonisation of stool samples was collected on different dates of the antibioticcourse, 30 days, and three months after the completion of the course. + indicates the sample isBlastocystis + and - indicates the sample is Blastocystis -.

Date	of	antibioti	c	Blastocystis
cou rse				+/-
Day 0				-
Day 2				+
Day 3				+
Day 4				-
Day 5				-
Day 6				-
Day 7				-
Day 8				+
Day 10				+
Day 15				+
30 days	after	course		+
3 mont	hs afte	er course		+



Figure 1. Heatmaps showing the relative abundance of taxa within the faecal samples, shown are all taxa which made up >1% of the total reads, all samples are indicated to be *Blastocystis* +ve (blue) or -ve (red) by a colour-coordinated legend. Dendrograms cluster both taxa (A-B) and the samples (B) using Euclidean distances and clustered using optimal leaf ordering. A). Heatmap showing the samples ordered by their collection timepoint during the antibiotics course. B). The heat map shows the samples ordered based on their similarity.



Figure 2. (A-C). Compositional plots showing the bacterial composition of the gut taxa aggregated to varying taxonomic levels. A). Phylum level B). Genus level C). species level. Taxa included made up >1% of total read counts respectively. Taxa abundances are shown as % relative abundance.



Figure 3. Statistical Diversity analysis of samples taken throughout the antibiotics course. A,B,C,D). Shannon, Chao1, Observed (richness), Simpson scores over time. Indicated if the sample was +ve (blue) or -ve (red) for *Blastocystis*.). Kruskal-Wallis H-test and Dunn's test (Bonferroni p-adjust method) or ANOVA and Tukey-HSD test were used for statistical analysis (this was based on normality of the data, determined using the Shapiro test). Kruskal Wallis/ANOVA scores were all shown to be >0.05 indicating no-significance between the samples.



Figure 4. Linear Discriminant Analysis (LDA) Effect Size (LEfSe) plot. LDA scores indicate the presence/increased abundance of each taxa to discriminate between two conditions, *Blastocystis* +ve (blue) and *Blastocystis* -ve (red). Taxa with LDA scores between -2 and 2 are considered insignificant 'biomarkers' and are not included in the plot.



Figure 5 Time course of metabolite abundances of four different groups of metabolites throughout the antibiotic course as well as *Blastocystis* Colonisation. a. SCFAs b. Amino acids. c. Sugars and Sugar alcohols d. Other important metabolites